“On a finite budget, the NHS cannot afford to offer every treatment on the market, so how is it decided which medications should be made available?
Award-winning director Adam Wishart follows the nail-biting decision about one drug, with unprecedented access to decision-makers the National Institute for Health and Clinical Excellence, the patients who need a life-extending treatment, and the American company that discovered and will profit from it.”
The programme will focus on access to the drug Revlimid for myeloma patients. The director, Adam Wishart, appeared on Radio 4’s Start the Week on 15th June. This programme is available indefinitely via the iPlayer.